Clinical Trial Update: Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects [Phase 3]

View source ↗

Summary

Phase 3 bioequivalence study of two Apremilast 30 mg tablet products completed in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Humanis Saglık Anonim Sirketi | Conditions: Psoriasis and Psoriatic Arthritis | Phase 3 | Status: COMPLETED